Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $6.1200 (0%) ($6.1200 - $6.1200) on Mon. Aug. 28, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.92% (three month average) | RSI | 37 | Latest Price | $6.1200(0%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -0.5% a day on average for past five trading days. | Weekly Trend | IOVA declines -7.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) SLV(44%) GDX(42%) GDXJ(40%) IPO(40%) IGOV(33%) | Factors Impacting IOVA price | IOVA will decline at least -2.46% in a week (0% probabilities). UUP(-41%) TAN(-40%) XME(-29%) XRT(-27%) XLP(-27%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.46% (StdDev 4.92%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-7.7(-225.82%) | Resistance Level | $6.78 | 5 Day Moving Average | $6.2(-1.29%) | 10 Day Moving Average | $6.39(-4.23%) | 20 Day Moving Average | $6.78(-9.73%) | To recent high | -31% | To recent low | 0.7% | Market Cap | $896m | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |